{"paper_id":"f9560b73-624d-4df2-ba24-c202d0411948","body_text":"Zusammenfassung\nDurch die rasche Entwicklung der verschiedenen Gonadotropin- Releasinghormon-Analoga (GnRH-Analoga) haben sich für die medikamentöse Behandlung der Endometriose neue Möglichkeiten ergeben. Die Gabe des GnRH-Analogons bewirkt einen reversiblen Hypoöstrogenismus durch die Down-Regulation der hypothalamisch- ovariellen Achse. In zahlreichen Studien konnte der günstige Einfluß von GnRH-Analoga auf die Endometriose dokumentiert werden [1–7]. In der vorliegenden, nicht vergleichenden, multizentrischen Phase-3-Studie wird über die Ergebnisse einer Untersuchung bei 104 Frauen mit Endometriose berichtet, die während einer Dauer von 6 Monaten mit dem GnRH-Analogon Leuprorelinacetat (Enantone®-Gyn Monats-Depot) behandelt wurden. Bei 70 dieser Patientinnen konnte bereits eine Follow-up-Periode von einem halben Jahr überblickt werden. Es war das Ziel dieser Studie, die Wirksamkeit, Sicherheit und Verträglichkeit von Leuprorelinacetat zu überprüfen.\nPreview\nUnable to display preview. Download preview PDF.\nSimilar content being viewed by others\nLiteratur\nShaw RW, Fraser HM, Boyle H (1983) Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis. Br Med J 287: 1667\nLemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone ( LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41: 863–871\nSchriock E, Monroe SE, Heinzl M, Jaffe RB (1985) Treatment of endometriosis with a potent agonist ol gonadotropin-releasing hormone (nafarelin). Fertil Steril 44: 583–588\nFranssen AMHW, Rolland R, Chadha DR, Willemsen WNP, Vemer HM (1986) Treatment with a luteinising hormone-releasing hormone analogue (buserelin) in danazol-resistant endometriosis patients. Eur J Obstet Gynecol Reprod Biol 23: 379\nFranssen AMHW, Kauer FM, Chadha DR, Zijlstra JA, Rolland R (1989) Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 51: 401–408\nSteingold KA, Cedars M, Lu JKH, Rändle D, Judd HL, Meldrum DR (1987) Treatment of endometriosis with a long acting gonadotropin-releasing hormone agonist. Obstet Gynecol 69: 403\nHenzl MR, Corson SL, Mohissi K, Buttram VC, Berqvist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 318: 485\nThe American Fertility Society (1985) Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 43: 351–352\nGerhard I, Bechtold E, Eggert-Kruse W, Heberling D, Runnebaum B (1990) Value of endometrial biopsies and serum hormone determinations in women with infertility. Hum Reprod 5: 906–914\nGerhard I, Becker T, Eggert-Kruse W, Klinga K, Runnebaum B (1991) Thyroid and ovarian function in infertile women. Hum Reprod 6: 338–345\nYamazaki I, Okada H (1980) A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocrinol Jp 27: 593–605\nDlugi AM, Miller JD, Knittle J (1990) Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo- controlled, double-blind study. Fertil Steril 54: 419–427\nDlugi AM, Rufo S, D’Amigo JF, Seibel MM (1988) A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 49: 913–916\nDmowski WP, Radwanska E, Binor Z, Tumman I, Pepping P (1989) Ovarian suppression induced with Buserelin or Danazol in the management of endometriosis. A randomized comparative study. Fertil Steril 51: 395–400\nKiesel L, Thomas K, Tempone A, Trabant H, Widra W, Runnebaum B (1989) Efficacy and safety of Buserelin treatment in women with endometriosis — a multicentre open-label study. Gynecol Endocrinol 3 [Suppl 2]: 5–19\nJohansen JS, Riis BJ, Hassager C, Moen M, Jacobson J. Christiansen C (1988) The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67: 701–706\nMatta WH, Shaw RW, Hesp R, Evans R (1988) Reversible trabecular bone-density loss following induced hypoestrogenism with the GnRH analogue Buserelin in premenopausal women. Clin Endocrinol 29: 45–52\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 1992 Springer-Verlag Berlin Heidelberg\nAbout this paper\nCite this paper\nGerhard, I., von Holst, T., Runnebaum, B. (1992). Endometriosetherapie mit Enantone®-Gyn Monats-Depot. In: Runnebaum, B., Breckwoldt, M. (eds) Leuprorelinacetat — Ein neues GnRH-Analogon. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77666-3_6\nDownload citation\nDOI: https://doi.org/10.1007/978-3-642-77666-3_6\nPublisher Name: Springer, Berlin, Heidelberg\nPrint ISBN: 978-3-540-55721-0\nOnline ISBN: 978-3-642-77666-3\neBook Packages: Springer Book Archive","source_license":"CC0","license_restricted":false}